OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC

June 27th 2024

Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.

Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL

June 27th 2024

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer

June 26th 2024

Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer.

Dr Parikh on Outcomes from the HERKULES-3 Trial in BRAF V600E–Mutant mCRC

June 26th 2024

Aparna Parikh, MD, discusses outcomes from the HERKULES-3 trial in BRAF V600E–mutated metastatic colorectal cancer.

Dr Ghia on Long-Term Efficacy With Acalabrutinib Monotherapy in CLL

June 26th 2024

Paolo Ghia, MD, PhD, discusses long-term follow-up data from a pooled analysis evaluating the efficacy of acalabrutinib monotherapy in CLL.

Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

June 26th 2024

James Ignatz-Hoover, MD, PhD, discusses the future of CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.

Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer

June 26th 2024

David Rimm, MD, PhD, discusses challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current diagnostic kits.

Dr Olazagasti on Culturally Tailored Lung Cancer Screening for Hispanic Head and Neck Cancer Survivors

June 26th 2024

Coral Olazagasti, MD discusses a tailored lung cancer screening program for Hispanic head and neck cancer survivors.

Dr Trent on the Efficacy of Bezuclastinib Plus Sunitinib in Pretreated GIST

June 26th 2024

Jonathan C. Trent, MD, PhD discusses bezuclastinib plus sunitinib in gastrointestinal stromal tumors with imatinib resistance or intolerance.

Dr Sekeres on Outcomes from the ASTREON Trial in Low- to Intermediate-Risk MDS

June 26th 2024

Mikkael A. Sekeres, MD, discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial.

Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC

June 26th 2024

Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.

Dr Bilusic on the Investigation of Enfortumab Vedotin in Rare GU Cancers

June 26th 2024

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Dr Heymach on Perioperative Durvalumab in Resectable N2 NSCLC

June 25th 2024

John Heymach, MD, PhD, discusses perioperative durvalumab in patients with resectable non-small cell lung cancer.

Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC

June 25th 2024

Joshua Linscott, MD, discusses using urinary cell-free tumor DNA to predict minimal residual disease in high-risk non-muscle invasive bladder cancer.

Dr Kyriakopoulos on Adding Cabazitaxel to Abiraterone/Prednisone in Patients With MCRPC

June 25th 2024

Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.

Dr Arnulf on Patient Factors and Biomarkers Impacting PFS With Ide-Cel in R/R Myeloma

June 25th 2024

Bertrand Arnulf, MD, PhD, discusses patient factors and pharmacodynamic biomarkers that impact survival outcomes with ide-cel in multiple myeloma.

Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD–positive AML

June 25th 2024

Harry Erba, MD, PhD, discusses the safety profile of quizartinib according to treatment phase and age in newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHL

June 25th 2024

Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.

Dr Siegel on Real-World Outcomes With Tandem Transplant in Newly Diagnosed Myeloma

June 25th 2024

David Samuel Dicapua Siegel, MD, discusses real-world outcomes with tandem transplantation in newly diagnosed multiple myeloma.

Dr Hauschild on the Role of Adjuvant/Neoadjuvant Therapy in Melanoma Management

June 25th 2024

Axel Hauschild, MD, PhD, discusses the role of adjuvant and neoadjuvant therapy in melanoma, highlighting the utility of perioperative approaches.